Splicing requires the accurate recognition of exonic sequences from the surrounding thousands of nucleotides of intronic sequence and is achieved by the coordinate interplay of splicing regulatory elements in genes and the trans-acting RNA and protein molecules to which they bind. Infidelity in this process can have dramatic consequences for protein production, with an errors resulting in mRNA instability or the production of aberrant protein products. It is therefore not surprising that disruptions of splicing processes have been associated with a wide range of diseases, including cancer. This review looks at some of the mechanisms that regulate splicing and how disruption of such mechanisms can contribute to cancer susceptibility and progression.
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REGULATION OF SPLICING

Splicing elements
Accurate excision of intronic sequences requires several sequence elements in the pre-mRNA including a 5′ splice site (5′ ss), branch point motif, poly-pyrimidine tract and 3′ splice site (3′ ss) (consensus splice sites; reviewed in (1, 2)). However, these features are not always sufficient to ensure accurate exon definition when exons, which usually average 150nt in length, are separated by intronic regions of up to 500,000nt. Additional sequence elements in introns (eg intronic splice enhancers (ISEs)) and in exons (eg exonic splice enhancers (ESEs)) can act to enhance exon recognition, whilst intronic splice silencers (ISSs) and exonic splice silencers (ESSs), can repress exon recognition (3). Other sequence elements can influence splicing by affecting RNA secondary structure.. For example, the weak 5′ ss of SMN2 exon 7 forms part of a stem-loop structure that impedes its recognition by the spliceosome thus repressing splicing (4). Structural elements located deep within introns function to ensure skipping of pseudoexons, and as such, disruption of these sequences can result in abnormal inclusion of pseudoexons in the final transcript. Examples of genes in which this has been reported include ATM and CFTR (5).
Splice site consensus sequences
Splice site consensus sequences were extensively surveyed in vertebrates during the 1980s, and are well conserved (6, 7) (see Figure 1) . The splice site consensus sequences can vary in strength, and in the case of weaker signals, other sequence elements may be required for exon recognition. The splice donor site consensus sequence is recognised by U1 snRNP, the branch point is recognised by U2 snRNP, the polypyrimidine tract and splice acceptor site are bound by U2AF.
Exonic splicing elements
Exonic splicing enhancers (ESEs) are sequence elements that promote exon inclusion and are required for constitutive splicing and are present in most, if not all, exons (8, 9) . Exonic splicing silencers (ESSs) are less well characterised. In contrast to ESEs, they repress exon inclusion and,appear to be more prevalent in pseudoexons and exons that are frequently skipped (10) . ESEs are generally recognised either by members of the SR protein family, or SR-like proteins (Table 1) , and ESSs are often recognised by members of the hnRNP family (11) .
The ESE prediction programs ESEfinder (12) and RescueESE (13) have recently become available, and there have now been a number of studies utilising these programs to identify sequence changes that exert pathogenic effects through disrupting ESE motifs. ESEfinder searches for consensus binding sequences for four SR proteins (SF2/ASF, SC35, SRp40 and SRp55) developed using the SELEX (systematic evolution of ligands by exponential enrichment) procedure (9, 12, 14) . Input sequences are given scores according to fit with the loose consensus sequences and motifs above a threshold value are predicted to be recognised by the SR proteins and act as ESEs. ESEfinder is currently limited to predicting ESEs recognised by only four of the family of SR proteins. RescueESE searches input sequences for a set of 238 hexamer sequence motifs found to be significantly enriched in exonic sequences when compared to intronic sequences, and also significantly enriched in exons with weak splice signals compared with exons with strong splice signals. The list of hexamers that RescueESE searches for were generated by a purely bioinformatic approach, and experimental validation has been performed for only 10 of the 238 motifs in an in vivo minigene system (15) . RescueESE is also limited in that it is unable to predict which splicing factors recognise each hexamer. Other limitations of these programs include their inability to take into account the interconnectivity of splicing to other regulatory processes, such as transcription, capping and polyadenylation (reviewed in (16)), which are very likely to influence the function of exonic splice enhancers.
Larger composite sequence elements that regulate splicing have also been characterised, such as CERES in exon 12 of CFTR (17) . Splicing enhancer predictor programs are unable to detect such elements, and so detection currently relies on techniques such as in vivo selection (18) or antisense microwalk (19) , both of which have been used to identify splicing elements in SMN2 exon 7. (GAC)n 27
1 Revised consensus sequences as per (1). R: A/G, S: C/G, M: A/C, W: A/U, Y: C/U, K: G/U Experimental approaches have also been used to identify functional ESS motifs. For example, using an artificial three exon minigene construct, Wang and colleagues were able to identify 141 decamers containing ESS motifs that induced skipping of the middle exon of the construct (10) . An additional minigene construct has also been employed to illustrate the ability of ESSs to influence splice site choice in exons with multiple 5′ splice sites or 3′ splice sites (20) .
Splicing factors
Regulation of splicing is mediated by the functional interactions of the above splicing elements with trans-acting regulatory factors, including the macromolecular RNA-protein complex known as the spliceosome and a wide range of RNA binding proteins, including SR proteins and hnRNPs.
Spliceosome
The molecular machinery responsible for accurate splicing is the spliceosome and it recognises intron/exon boundaries in the pre-mRNA transcript and is able to catalyse the cut-and-paste reactions of intron removal. Splicing is reliant on the accurate recognition of authentic splice sites from the many pseudo-splice sites present, and the ability of the spliceosome to recognise appropriate splice site consensus sequences relies on the complex coordinated network of sequence signals embedded in both introns and exons surrounding the splice sites and the proteins that interact with them (3, 11, 21) (see Figure 1 ).
SR proteins
SR proteins are highly conserved RNA-binding proteins characterised by one or more amino-proximal RRM-type RNA binding motifs, and a distinctive carboxylterminal domain rich in arginine-serine dipeptides (RS domain) of variable length (reviewed in (22, 23)). Members of the SR protein family include: ASF/SF2, SC35, 9G8, SRp30c, SRp20, SRp40, SRp46, SRp55, SRp75, and p54 (reviewed in (23) ). The highly conserved RRM domains bind to the pre-mRNA, while the RS domain binds proteins and recruits the splicing apparatus and aids splice site pairing (24) . These properties aid in splice site recognition and promote the inclusion of the exon in the final mRNA. SR proteins predominantly bind to exonic splicing enhancers (ESEs; see Section 2.2.2) however in certain circumstances they are also able to bind 'intronic splice enhancers' (ISEs) to promote recognition of nearby splice sites (25) . SR proteins have been shown to influence the selection of alternative splice sites in a concentration dependent manner (9, 14, (26) (27) (28) (29) . An increased SR protein concentration results in the selection of the proximal 5′ ss in pre-mRNAs with multiple 5′ ss (30, 31) . Tissue specific variations in the total and relative amounts of SR proteins or their mRNAs have been described (28, 32) and SRp55, as one example, is expressed at low levels in the brain which contributes to the tissue specific alternative splicing profile of calcitonin mRNA (33) . SR protein expression changes during T-cell activation, and there are differences in concentrations of a number of SR proteins in memory Tcells compared to activated T-cells (34) with concomitant changes in alternatively spliced isoforms of CD44 and CD45 (35) . A direct link between these changes in SR protein expression and CD44 and CD45 isoform expression has not yet been established, although hnRNP A1 and hTra2-β regulate splicing of CD44 variable exon 5 (36, 37) . Also, there are some tissue specific splicing factors, such as NOVA-1, which is only expressed in neurons (38) . It has been proposed that variations in splicing factor expression between tissues is the major contributing factor to tissuespecific alternative splicing (24, 39) .
hnRNPs
Heterogeneous nuclear ribonucleoproteins (hnRNPs) have been implicated in multiple aspects of RNA processing including splicing, transport, mRNA stability, translational silencing and polyadenylation (reviewed in (40) ). hnRNP A1 and hnRNP I (Pyrimidine Tract Binding Protein; PTB) are the most well characterised splicing factors and are associated with exon skipping, although some hnRNPs have been shown to act as splicing activators (41) . hnRNPs are thought to block exon recognition by simply preventing SR proteins from binding to their sites in the exonic region, resulting in exon skipping (42) . Like SR proteins, the activity of hnRNPs is concentration dependent and also affected by phosphorylation. The concentration of individual hnRNPs also varies across cell and tissue types (43) .
Overexpression of hnRNPs has the opposite effect to overexpression of SR proteins on splice site selection (24) , suggesting that the silencing ability of hnRNPs is concentration dependent in the same manner as SR proteins and their enhancing ability. It has also been shown that splice site selection in protein 4.1R exon 16 alters with hnRNP A/B protein concentrations during erythropoesis (44) .
DEFECTS IN SPLICING OF CANCER ASSOCIATED GENES
Defects in splicing have now been implicated in many diseases, such as growth hormone deficiency, Frasier syndrome, Parkinson's disease, cystic fibrosis, retinitis pigmentosa, spinal muscular atrophy, myotonic dystrophy and a large number of cancers (reviewed in (21, (45) (46) (47) ). Splicing defects can arise as a result of sequence mutations that disrupt splicing elements or through the unbalanced expression or normal alternative splice variants. 
Mutations in splicing elements
It has been estimated that around 15% of point mutations that result in disease cause defects in RNA splicing (48) . This estimate is only based on classical consensus sequences and does not consider other splicing motifs such as ESEs, so the real proportion may be closer to 50% (1). Most single nucleotide mutations that alter constitutive splicing generate aberrant transcripts as a result of exon skipping or the use of cryptic splice sites. In many cases these result in loss of expression through generation of isoforms that lose the open reading frame and are targeted for nonsense mediated decay (NMD; see Section 4.1).
Mutations in consensus splice sites
Small deletions and single nucleotide mutations that disrupt normal splicing processes by adversely affecting splicing consensus sequences have been detected in a range of cancer-related genes, although not all single nucleotide changes in the splice consensus sequences result in abnormal splicing (for e.g. (49) and (50)).
Some examples of mutations at the 3′ end of exons that disrupt splice sites are found in the DNA mismatch repair gene MLH1. MLH1 667G>A is located in the last nucleotide of exon 8, and 1667G>T is the final base of exon 14. However, two different effects are seen from these mutations. 667G>A results in complete skipping of the 89bp exon 8 which creates a frameshift, and the aberrant transcript is likely to be subjected to NMD resulting in a loss of expression (51). 1667G>T does not result in exon skipping, however the allele generates a transcript retaining 88bp of intron 14 before utilising a cryptic splice site. This intronic region contains an in-frame stop codon, and the aberrant splice transcript is also likely to be subject to NMD (51) . In the breast cancer susceptibility gene BRCA1, the silent mutation BRCA1 4304G>A is located at the last nucleotide of exon 12 and results in complete skipping of the exon leading to a loss of the ORF (52) , and the ORF is also lost by skipping of BRCA2 exon 13 induced by the mutation 7235G>A, which is located at the final base of the exon (53) . A sequence change in the last base of BRCA1 exon 23, 5586G>A, generates transcripts lacking exon 23 which results in a frameshift and an altered C-terminus of the protein without induction of NMD as exon 24 is the final exon (54) . Some exon skipping events arising due to mutation still retain the ORF, for example BRCA2 8204G>A is located at the final base of exon 17 and encodes a protein lacking the 57 amino acids encoded by the exon (55). Splice site mutations can also invoke the use of cryptic splice sites, such as BRCA1 330A>G, which is located at the second last base of exon 5. This mutation results in the use of a cryptic splice site 22nt upstream in preference to the authentic splice site, leading to a loss of the ORF and a PTC in exon 6 (56) .
Mutations in the first base of an exon can also disrupt splicing consensus sequences. The 'missense' mutation 423G>T in the first nucleotide of exon 4 of the tumour suppressor gene APC results in skipping of the exon (49) .
Intronic mutations in splice donor sequences can also disrupt splicing. A number of examples can be found involving the tumour suppressor PTEN. A mutation in the first base of intron 3, IVS3+1G>A, results in complete skipping of exon 3, as does the mutation at position 5 of the intron, IVS3+5G>A (50) . The PTEN-∆3 transcript maintains the ORF, but has severely reduced protein phosphatase ability (50) . The mutation IVS3-1G>A is located in the final nucleotide of PTEN intron 3, and leads to complete skipping of exon 4, a loss of the ORF and induction of the NMD pathway (50) . Mutations in the splice donor site consensus sequences of BRCA1 and BRCA2 have been shown to create a range of splicing abnormalities ( Figure 2 ). Aberrant transcripts generated in this manner that lose the ORF can occur by exon skipping (e.g. BRCA1 IVS8+2T>C (57) and BRCA2 IVS2+1G>A (58)), use of a cryptic splice site inside an exon (e.g. BRCA1 IVS7+1G>A (59)), and use of a cryptic splice site in the intron and intron retention (e.g. BRCA1 IVS17+1G>T (60)). Mutations in the splice donor site sequences can generate multiple aberrant transcripts, with BRCA1 IVS19+2delT generating two transcripts with altered reading frames; BRCA1-∆19 and BRCA1-∆18-19 (52) , and BRCA2 IVS6+1G>A which generates two transcripts which both lose the ORF: BRCA2-∆5 and BRCA2-∆5-6 (52).
Splice acceptor site consensus sequences can also be affected by intronic mutations, and mutations that disrupt endogenous splicing in this way have also been reported for both BRCA genes (Figure 3) . Two mutations in BRCA2 disrupt the final nucleotide of the intron resulting in exon skipping. BRCA2 IVS7-1G>A generates transcripts lacking exon 8, and BRCA2 IVS17-1G>C generates transcripts that have skipped exon 18 (61), both events leading to a loss of the open reading frame. BRCA2 IVS17-1G>C may also increase the amount of BRCA2-∆17-18 transcripts (61). BRCA2 IVS20-2A>G also leads to generation of 2 splice variants. The mutation invokes the use of a cryptic splice site 43bp into exon 21, and this splice site use can occur in combination with a 93bp insertion from intron 20. Both of these aberrant transcripts contain PTCs (59) . In BRCA1, the IVS10-2A>C mutation leads to skipping of exon 11 (62) . While BRCA1-∆11 is a naturally expressed isoform, the imbalance of this isoform relative to the full length is associated with breast cancer (62) . The BRCA1 mutation IVS3-6T>G results in a fivefold increase in the amount of BRCA1-∆5 transcripts above normal expression (63) . BRCA1-∆5 transcripts retain the open reading frame after skipping 26 amino acids and disrupting the highly conserved RING domain.
Mutations outside the invariant dinucleotides can also disrupt splicing, with BRCA1 IVS16+6T generating transcripts that use a cryptic splice donor site which is more similar to the consensus sequence than the authentic exon 16 splice site. Using this cryptic splice site leads to incorporation of the first 69 nucleotides of intron 16, which incorporates 2 stop codons (59, 64) . However, not all aberrantly spliced transcripts lose the ORF. BRCA1 IVS 3+3A>C leads to the skipping of exon 3, which results in deletion of 18 amino acids from the highly conserved RING domain of BRCA1 but retains the remainder of the ORF (52) . Furthermore, mutations in PTCH, associated with nevoid basal cell carcinoma syndrome (NBCCS), include PTCH IVS6+5G>T, which results in the use of a cryptic donor splice site inside exon 6 which skips the final 87bp of the exon, and an in-frame loss of 29 amino acids (65).
Mutations that disrupt ESEs
Mutations that adversely effect ESE motifs, can result in failure of SR proteins to recognise and bind to the motif, which in turn leads to failure of the spliceosome machinery to recognize the exon, resulting in exon skipping (66) . Mutations that disrupt ESS motifs would be predicted to result in increased exon inclusion, however as yet no such mutations have been reported.
A series of missense and nonsense mutations well inside exon boundaries of NF1 were examined for the Adapted from (67) . 1 First number indicates the distance in nt to 3′ splice site, and the second number indicates the distance in nt to the 5′ splice site.
2 Based on minigene construct splicing assay.
potential to disrupt ESEs and create splicing abnormalities. These mutations resulted in increased exon skipping from 4-100fold above normal levels (67) . The exons were then screened using ESEfinder and RescueESE for potential ESE motifs that were disrupted by the mutations. Some of the mutations resulted in clear losses of predicted ESEs, while others yielded more ambiguous results and a selection is shown in Table 2 . This study highlights the limitations of the current ESE prediction programs, which arise as a result of the highly degenerate nature of ESE motifs and the inability to factor in other important variables, such as distance from the splice site and splice site strength and effects of simultaneous gene regulatory events.
Only a small number of mutations in the BRCA genes have been verified as disrupting ESE motifs leading to splicing abnormalities. A nonsense mutation in exon 18 of BRCA1, 5199G>T, has been shown to disrupt an ESE motif recognised by SF2/ASF and only generate transcripts that skip the exon (66) . There is a single nucleotide change in BRCA2 exon 18, 8393C>G, that disrupts three predicted ESE motifs and generates transcripts lacking the exon (68) . A number of unclassified sequence variants in BRCA1 and BRCA2 have been predicted to disrupt ESE motifs however these remain to be verified experimentally (69) . .
Mutations that create or disrupt other splicing sequences
Single nucleotide changes can alter splicing processes independent of the splicing consensus sequences and ESE motifs. A SNP in KLF6 which is associated with increased prostate cancer risk (IVS1-27G>A) generates a novel SRp40 binding site in the intron, and increases transcription of three alternatively spliced isoforms which, when translated, are mislocalised to the cytoplasm and antagonise the function of the authentic isoform (70) . A mutation deep in intron 2 of PTEN, IVS2-38insG, disrupts the consensus branch site sequence, and leads to skipping of exon 3 (50).
Mutations have also been identified in BRCA1 that alter splicing processes independent of authentic splice sites and ESEs. BRCA1 309T>G is predicted to cause a missense change in the highly conserved RING domain of BRCA1, however the mutation promotes the use of a cryptic splice site in exon 5 which is 22bp prior to the authentic 3′ ss. Utilisation of this cryptic splice site results in a loss of the reading frame and the transcript is predicted to be targeted by NMD (71) . The mutation BRCA1 IVS5-12G>A creates a new cryptic splice site new site 11nt prior to exon 6 in BRCA1, leading to incorporation of 11nt of the intron and therefore loss of the ORF (72).
Dysregulated expression of splicing factors
Alteration in the concentration of specific splicing factors is believed to contribute to the increased alternative splicing isoforms generated in disease. A number of studies have now shown that the expression levels of individual SR proteins can differ between tumour tissue and the corresponding normal tissues. For example, the expression of SRp20 is induced during development of mammary carcinogenesis, exhibiting a progressive increase in expression as normal cells which alter to pre-neoplasias and then progress to tumours (73) . A more recently detected member of the SR protein family, SR-A1, has been found to be overexpressed in aggressive ovarian cancers (74) . A more extensive study of ovarian tumours found that SC35 and SF2/ASF show a marked increase in expression compared to normal tissue, SRp20 showed a slight increase while SRp40 and SRp55 expression remained constant (75) . These studies suggest that there is specific induction of certain splicing factors rather than a general increase in the expression of all the components of the splicing machinery. This specific induction also extends to SR-like proteins, as hTra2β expression is increased in ovarian tumours, while hTra2α expression remains constant (75) .
The alteration of normal splicing factor expression levels is likely to induce changes in splicing across the transcriptome, and already there are numerous reports of increases in expression of alternatively spliced mRNAs from specific genes in tumour tissue compared with normal counterparts. One example is TSG101, expression of which is important for genomic stability, cell cycle regulation and suppression of malignant growth. While normal cells express a range of TSG101 isoforms (76, 77) , there have been numerous observations of an increase in the expression of multiple alternatively spliced transcripts in tumour samples from breast, ovary, prostate, thyroid, and cervical tissues (for e.g. (76-79) ). Consequences of genes that undergo increased alternative splicing in disease are described in Section 4.2. What remains unclear is whether altered splicing is an early event trigger of tumourigenesis, or whether it is symptomatic of the general breakdown of cellular processes during disease progression. Related to this is the question of what triggers this change from the normal splicing factor concentrations to generate the altered expression of splice variants. 
∆N-p53
(p47) p47 is generated from p53 transcripts that retain intron 2, and utilise an intiation codon in exon 4 which lack the first 39 amino acids of p53. p47 lacks the first transactivation domain.
Unknown. p47 is able to dimerise with p53, inhibits p53 mediated transcription, also contributes to cytoplasmic mislocalisation. p47 impairs p53-mediated growth suppression. Also unable to complex with mdm2 and accumulate in response to DNA damage.
113, 114
p73 ∆N-p73 ∆N-p73 is an N-terminal deletion isoform which arises from incorporation of additional exon (exon 3') and use of translational start site in 3'. This isoform lacks the putative transactivation domain of p73.
∆N-p73
is frequently overexpressed in cancers (ovary, endometrium, cervix, vulva, vagina, breast, kidney, and colon) but not normal tissues.
∆N-p73 is able to suppresses p53 and p73 transcriptional activation. ∆N-p73 is also able to inhibit p53 suppression of colony formation.
115-117
WISP1
WISP1v
Lacks exon 3 which results in loss of a module of Von Willebrand type C which is thought to participate in protein complex formation. 
Dysregulated expression of splice variants
Changes in the endogenous alternative splicing patterns of genes in cancer may contribute to disease progression via a range of mechanisms that confer a selective advantage to cells housing such changes. Proteins generated by alternatively spliced mRNA isoforms may act as dominant negatives on their full length counterparts, while others may have entirely novel functional properties. Both of these eventualities can have dramatic implications for disease progression. Table 3 summarises some examples of splice variants overexpressed in cancer that possess functional properties that distinguish them from their full length counterparts and implicate the isoforms in disease progression, whilst the text below highlights some specific examples.
The breast cancer susceptibility gene BRCA1 consists of 24 exons and expresses a large number of splice variants in a tissue-specific manner (reviewed in (80)). Several studies have found that four predominant BRCA1 mRNA variants-full length, ∆9-10, ∆11q, and ∆9-10-11q-are expressed in a variety of tissues under different conditions (81-83). Another significant splice variant of BRCA1 is BRCA1-∆11, which is also expressed in the mouse (84) . These splice variants all maintain the open reading frame, and their protein products retain some of the full length activity in functional assays.
The expression of alternatively spliced BRCA1 isoforms in normal and malignant tissue is poorly understood. Conflicting studies have confounded attempts to characterise BRCA1 splicing in such a context. For example, in normal and malignant breast epithelial cells, the full length BRCA1 and ∆11q isoforms were the higher expressed isoforms, compared to ∆9-10 and ∆9-10-11q (83), whereas in other breast and ovarian tumours the ∆9-10 variant was highly expressed and lower amounts of ∆11q were detected (85) . The conflicting results of these studies may reflect the heterogeneity of different tumour samples as well as different methodologies. The expression of the predominant BRCA1 splice variants has also been examined across multiple cell lines using a multiplex PCR protocol (81). Expression of the full length BRCA1 made up ~80% of the pool of BRCA1 transcripts in normal breast tissue, whereas in MCF7 cells, a tumourigenic mammary epithelial cell line, expression was reduced to 50% of the total pool. In MDA-MB-231 cells, a more aggressive tumourigenic mammary epithelial cell line expression of the full length was reduced to ~35%. With the decrease of full length BRCA1 expression, the expression of BRCA1∆9-10 increased from 8% in normal breast tissue to 24% in MCF7s, and 44% in MDA-MB-231s. This increase in expression correlates to increased invasive activity of the cell lines (86), or it may be representative of cell type as MCF7 cells display a luminal phenotype whereas MDA-MB-231 cells express a range of mesenchymal markers.
BRCA1-IRIS is another BRCA1 splice variant and is generated by continuation of the transcript into intron 11 in preference to splicing exon 11 to exon 12. The transcript encodes a protein which has an identical 1365 amino acids to the full length BRCA1, prior to a novel 34 amino acid Cterminus. Expression of the two isoforms is inconsistent across both the cell cycle and tissue types, with BRCA1-IRIS mRNA expression five times higher in white blood cells than the full length (87) . In response to acute DNA damage full length BRCA1 forms nuclear foci, while BRCA1-IRIS does not, and only the full length BRCA1 protein associates with BARD1 (87). BRCA1-IRIS is exclusively chromatin-associated and is a positive influence on DNA replication, as it associates with proteins that bind to initiation sites of DNA replication, such as ORC1, Cdc6 and MCM2 (87) . In a follow up study, Nakuci and colleagues were able to show that BRCA1-IRIS also forms complexes with SRC1 and SRC3, nuclear receptor coactivators, and is recruited to the cyclin D1 promoter, inducing cyclin D1 expression and in turn, cellular proliferation (88) . This is in contrast to a number of other studies showing that full length BRCA1 can inhibit cell cycle progression and in turn cellular proliferation (89-91). These data suggest that despite the sequence similarity, BRCA1-IRIS may act as a proto-oncogene while the full length BRCA1 acts as a tumour suppressor.
The breast cancer susceptibility gene 2 (BRCA2) consists of 27 exons and to date only nine isoforms, including the full length, have been reported as expressed in normal tissues. One of these is BRCA2 ∆3, which has been shown to be has been found expressed in a range of normal tissues as well as in cancerous samples (92) . While the skipping of BRCA2 exon 3 maintains the ORF, it results in loss of the transcriptional activation domain (92, 93) . The protein domain encoded by BRCA2 exon 3 shows sequence similarity to the activation domain of c-Jun, and this region has been shown to possess transcriptional activation activity (94) .
Another BRCA2 splice variant that has been detected as expressed in normal breast tissue is the BRCA2-∆12 isoform (95) . Exon 12 is 96bp long, and skipping of the exon maintains the open reading frame, however it is unclear if any protein interaction domains are interrupted by this exon skipping event. Brca2-∆12 is also expressed in the mouse, and this evolutionary conservation suggests that the isoform may perform specific functions in the cell (95) . When breast tumour samples were analysed for BRCA2-∆12 expression, 4/12 showed higher expression of the isoform than their matched normal controls and this higher expression was associated with steroid receptor negativity (95) . Further work is required to determine what functional role BRCA2-∆12 performs and to establish whether there is any correlation between BRCA2-∆12 overexpression and breast or ovarian cancer.
CHK2 is a DNA damage checkpoint kinase. CHK2 is subject to extensive alternative splicing in cancers, with more than 90 variants detected in a panel of 53 breast carcinomas in addition to the full length isoform (96) . In normal breast tissue an average of four alternatively spliced isoforms were detected, while in breast tumours an average of six isoforms were found (96) . Over half of the splice variants detected contained PTCs, which may make them targets of the NMD pathway, while other splice variants were aberrantly localised to the cytoplasm (96) . These two mechanisms, NMD and aberrant subcellular localisation, would significantly reduce the available pool of functioning CHK2 in these tumours.
PTEN is a dual-phosphatase tumour suppressor which is able to dephosphorylate PIP3, the PDK1 activator. Inactivated PTEN results in unregulated activation of Akt/PKB, resulting in uncontrolled proliferation. PTEN also inhibits the MAPK pathway, and is able to elicit apoptosis and cell cycle arrest at G1. Inactivation of PTEN is found in 85% of Cowden syndrome (characterised by increased risk of breast and thyroid cancer) cases, and PTEN inactivation is also associated with a variety of sporadic cancers. There are 11 natural splice variants of PTEN including the full length isoform. Eight isoforms were identified by Agrawal and Eng (97) . These isoforms have premature termination codons and are expressed normally at varying levels in different tissues. The presence of these PTCs may target these isoforms for NMD, as alternatively spliced isoforms of PTEN containing PTCs are rapidly degraded prior to generating any protein (50) . Full length PTEN expression was shown to be reduced in 10/12 sporadic breast cancers, as were some of the splice variants, while expression of the PTEN-5b splice variant Ref:
Reference mRNA was increased in 9/12 sporadic breast cancers (97) . The increased alternative splicing of PTEN results in the generation of a number of isoforms containing PTCs and these are predicted to be targets of the NMD pathway, which may be an effective means of severely reducing the amount of functional PTEN in the tumour cells.
WT1-KTS-is an alternatively spliced isoform of WT1 which is overexpressed relative to the WT1-KTS+ isoform in patients with Frasier Syndrome. In the majority of cases, this imbalance of alternative splicing arises due to mutations in WT1 which disrupt normal KTS+ splicing (see for e.g. (98)). These two isoforms of WT1 possess transactivation activity, however transactivate a different selection of target genes (99) . This is an example of splicing disruption arising from mutations in the gene which leads to disease. Other cases of disease-associated disruptions in alternative splicing do not necessarily arise due to gene mutations, with WT1-∆5, another WT1 isoform overexpressed in breast tumours relative to normal tissues (100). As WT1-∆5 is expressed normally, this is an example of disrupted regulation of alternative splicing, leading to an increase in expression of one particular isoform. The WT1-∆5 is hypothesized to have a reduced capacity to repress transcriptional activation compared to the full length isoform (100). In some cases, certain alternatively spliced isoforms are found to be expressed in tumours originating from tissues that do not express the alternatively spliced isoform normally. Androgen receptor (AR) has been shown to express an isoform lacking exon 3 in breast cancers and breast cancer cell lines, however no isoform is detectable in normal breast tissue (101) . The AR-∆3 protein product is predicted to confer a reduced activation of growth inhibitory genes compared to the full length AR (101).
CLINICAL IMPLICATIONS OF SPLICING DEFECTS IN CANCER
Tumour biomarkers
The expression of alternatively spliced isoforms that are unique to cancerous tissue can present biomarkers for disease and also treatment targets. Detecting the expression of these unique isoforms may have clear diagnostic and prognostic value. In addition, these novel isoforms may supply cancer specific epitopes able to be recognised by the immune system, and may serve as targets for immunotherapy. Over 1450 different potential tumour antigens have been identified using the SEREX approach (serological identification of antigens by recombinant expression cloning) (reviewed in (47) ). Some examples of alternatively spliced isoforms that may potentially act as biomarkers are shown in Table 4 . Other potential biomarkers are listed in Table 3 , such as AR-∆3 and osteopontin-c, both potential biomarkers of breast cancer.
Therapeutic strategies for correcting splicing defects
New techniques are currently being established to correct splicing abnormalities that are associated with disease. One such technique involves the use of oligonucleotides targeted to splicing sequence motifs. These oligonucleotides, commonly morpholinos, are resistant to nucleases and do not allow degradation of mRNA in RNA-olgionucleotide hybrids by RNase H. The clinical implications of correcting splicing abnormalities are illustrated in the following examples.
β-thalassemia results from mutations that cause defective β-globin expression, and result in protein deficiency. Splicing mutations are among the most common mutations causing defective β-globin expression, and some of the most common splicing mutations activate aberrant splice sites, even though correct sites remain potentially functional. Two mutations located deep within intron 2, IVS2-654C>T and IVS2-745C>G, both create an aberrant 5′ ss and use a common cryptic 3′ ss at 579, leading to inclusion of intronic sequence in the β-globin mRNA which includes a stop codon preventing proper translation of the mRNA. The ultimate consequence of these mutations is β-thalassemia resulting from β-globin deficiency. Antisense morpholinos to these aberrant splice sites in mutant β-globin pre-mRNAs were able to restore correct splicing and translation of β-globin mRNA in mononuclear cells from peripheral blood of thalassemic patients (102) (see Figure 4) . The repaired expression reached around 30% of that of the normal, and was still detectable nine days after morpholino treatment.
Antisense oligonucleotides have also been used to re-direct dystrophin pre-mRNA processing by blocking sequences crucial to splicing. Duchenne and Becker muscular dystrophies arise due to mutations in dystrophin, with Duchenne muscular dystrophy usually characterised by the absence of functional dystrophin protein.
Morpholinos targeted to the dystrophin pre-mRNA are able to induce skipping of specific exons of the pre-mRNA transcript in order to maintain the ORF, which may be disrupted by frameshift mutations or splicing mutations, or to skip nonsense mutations (103-105) (see Figure 5 ). These morpholinos can target one exon specifically, or are able to be used in a cocktail to induce skipping of multiple exons. Morpholinos can be targeted to the splice consensus sequences, however they are marginally more effective when targeted to ESE motifs (103) . Morpholinos are also able to be injected into muscular tissue in the absence of a delivery reagent (103) .
While morpholinos are able to induce skipping of exons, enhancing the inclusion of exons has also been examined. Cartegni and Krainer were able so restore splicing in two systems involving ESEs which had been abrogated by single nucleotide sequence changes (106) using a PNA-peptide approach termed 'ESSENCE' (exonspecific splicing enhancement by small chimeric effectors). A peptide nucleic acid (PNA) sequence complementary to the mutant pre-mRNA fused to a peptide containing 10 RS repeats was able to act in place of an SR protein and restore splicing in both a BRCA1 minigene system and an SMN2 minigene system (see Figure 6 ). This study shows that specifically designed molecules may be able to restore splicing of exons that would otherwise be skipped.
CONCLUSIONS AND PERSPECTIVES
The dramatic effects of dysregulated splicing can arise due to cis sequence mutations in the pre-mRNA, or an Figure 6 . Restoration of exon inclusion in instances of mutated ESEs.In the restored mutant the PNA oligo fused to the RS repeats binds to the mutant sequence and is able to carry out the protein-protein interactions of the normal SR protein (106) . imbalance in trans splicing factors or splice variants. Future research in the field of splicing and cancer will include more reliable identification of functional splicing elements and a better understanding of the extent and functional consequences of alternate splicing in cancerassociated genes and the contribution such variants make to the tumourigenic process.
In terms of identifying functional splice elements, there is much interest in the role of ESEs. It has been suggested that ESEs are present in all exons, whether constitutively or alternatively spliced (1). However, the computer programs that predict ESE motifs often yield high numbers of false positive results and ambiguous results (67, 69) . The ability to identify functional ESE motifs from these outputs results remains a challenge, however applying filters to the output data of these predictions programs may improve their accuracy (69) .
Alternative isoforms can have pathogenic effects through either deficiency in the amount of functional full length protein or through novel characteristics or altered functional capabilities to those of the full length. A complete characterization of the expression and function of all splice variants arising from all cancer associated genes will be required in order to determine the precise role of splice variants in cancer. Projects such as the ENCODE project will achieve this (107). Data from the recently described pilot ENCODE certainly underscore the number and diversity of alternate transcripts, predicting an average of 5.4 alternate transcripts per locus (108) . Future priorities include determining the functions of these alternate transcripts and their relative expression in normal and tumour cells. 
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